Short interest in Biomea Fusion, Inc. (NASDAQ:BMEA) saw a significant decline in May. As of May 31st, there was short interest totaling 11,930,000 shares, a decrease of 9.2% from the May 15th total of 13,140,000 shares. The days-to-cover ratio is currently 9.8 days based on an average daily trading volume of 1,220,000 shares. Currently, 42.9% of the shares of the company are short sold. Several research analysts have issued reports on the company, with Scotiabank dropping their target price on Biomea Fusion from $41.00 to $21.00 and setting a 'sector outperform' rating on the stock. Oppenheimer also dropped their price objective on Biomea Fusion from $70.00 to $60.00 and set an 'outperform' rating on the stock. JPMorgan Chase & Co. increased their price objective on Biomea Fusion from $14.00 to $15.00 and gave the stock a 'neutral' rating. Truist Financial downgraded Biomea Fusion from a 'buy' rating to a 'hold' rating. HC Wainwright reduced their price objective on Biomea Fusion from $50.00 to $15.00 and set a 'buy' rating on the stock. The stock has a consensus rating of 'Moderate Buy' and a consensus target price of $28.25. Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company reported a quarterly loss of ($1.09) per share, missing the consensus estimate of ($1.02) per share. Analysts anticipate that Biomea Fusion will post earnings per share of -4.09 for the current fiscal year. The stock is currently trading at $5.09, with a market capitalization of $182.93 million. [b1d22e6a]